Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiovascular risk often goes unaddressed in prostate cancer patients

Key clinical point: Approximately half of prostate cancer patients received risk assessment for cardiovascular disease; nearly one-third of those with uncontrolled risk factors were not receiving medication to reduce their risk.

Major finding: In a population of veterans with prostate cancer, 68.1% underwent comprehensive assessment for cardiovascular risk factors; 54.1% of those assessed had uncontrolled risk factors, and 29.6% of those with uncontrolled risk factors were not receiving medications to address those factors.

Study details: The data come from a cross-sectional analysis of 90,494 U.S. veterans diagnosed with prostate cancer between January 1, 2010, and December 31, 2017; 25% received androgen deprivation therapy, which may increase cardiovascular risk.

Disclosures: The study was supported by a NIH Cancer Clinical Epidemiology training grant to lead author Dr. Sun, a VA Center for Health Equity Research and Promotion Pilot Grant and a NIH Agency for Health Research and Quality grant to coauthors, and funding from the Penn Cardio-Oncology Translational Center of Excellence. Lead author Dr. Sun had no financial conflicts to disclose.


Sun L et al. JAMA Netw Open. 2021 Feb 1. doi: 10.1001/jamanetworkopen.2021.0070.